Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117599 | 0.92 | MAPK14 (0.64) | MAPK14MAP2K1MAPK11ALDH1A1SMN1; SMN2 | |
| SCHEMBL5114250 | 0.84 | MAPK14 (0.64) | MAPK14MAP2K1MAPK11ALDH1A1SMN1; SMN2 | |
| SCHEMBL5898946 | 0.84 | MAPK14 (0.60) | MAPK14ALDH1A1SMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL5220199 | 0.83 | MAPK14 (0.50) | MAPK14MAP2K1MAPK11SMN1; SMN2 | |
| SCHEMBL5122607 | 0.77 | MAPK14 (0.60) | MAPK14MAP2K1MAPK11 | |
| SCHEMBL5124039 | 0.77 | MAPK14 (0.63) | MAPK14MAP2K1MAPK11ALDH1A1SMN1; SMN2 | |
| SCHEMBL3072596 | 0.76 | MAPK14 (0.82) | MAPK14MAP2K1MAPK11LCKCSF1R | |
| SCHEMBL14078304 | 0.75 | MAPK14 (0.71) | MAPK14MAP2K1MAPK11ALDH1A1HSD17B10 | |
| SCHEMBL5216080 | 0.74 | MAPK14 (0.88) | MAPK14MAP2K1MAPK11 | |
| SCHEMBL4855098 | 0.74 | MAPK14 (0.77) | MAPK14MAP2K1MAPK11ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1499600-B1 | HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060089393-A1 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2006-04-27 | — | — | US | disclosed |
| EP-1499600-A1 | HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003093248-A1 | HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089393-A1 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 8/4885MAP2K1 67/4885MAPK11 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.